Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma

被引:124
|
作者
Sugiura, Teiichi [1 ]
Uesaka, Katsuhiko [1 ]
Kanemoto, Hideyuki [1 ]
Mizuno, Takashi [1 ]
Sasaki, Keiko [2 ]
Furukawa, Hiroyoshi [3 ]
Matsunaga, Kazuya [1 ]
Maeda, Atsuyuki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka 4118777, Japan
关键词
Pancreatic cancer; CA19-9; Early recurrence; GEMCITABINE-BASED CHEMORADIATION; COMPUTED-TOMOGRAPHY; RESECTABLE ADENOCARCINOMA; BILIARY DRAINAGE; TUMOR-MARKER; CA-19-9; SURVIVAL; CHEMOTHERAPY; CANCER; THERAPY;
D O I
10.1007/s11605-012-1859-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value. One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study. Univariate and multivariate analyses were performed to determine the predictors of early recurrence which was defined as relapse within 6 months after surgery. On ROC curve analysis, the cutoff value of CA19-9 was determined to be 100 U/ml. Of 73 patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml, 39 (53 %) had early recurrence. In contrast, only 9 of 81 patients (11 %) with CA19-9 value < 100 U/ml developed a recurrence at an early period (p < 0.001). Multivariate analysis revealed that CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (odds ratio, 11.2) were significant predictors of early recurrence. The overall 3- and 5-year survival rates and median survival times were 47.3 %, 40.1 %, and 31 months in patients with CA19-9 value < 100 U/ml and 21.2 %, 9.4 %, and 16 months in patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (p < 0.001). A preoperative CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml was a significant predictor of early recurrence and a poor prognosis after resection for pancreatic adenocarcinoma.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [21] Predictive Value of Serum CEA, CA19-9 and CA72.4 in Early Diagnosis of Recurrence after Radical Resection of Gastric Cancer
    Li, Yan
    Yang, Ying
    Lu, Ming
    Shen, Lin
    HEPATO-GASTROENTEROLOGY, 2011, 58 (112) : 2166 - 2170
  • [22] Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreatic ductal adenocarcinoma
    Chang, Shaofei
    Liu, Yaohua
    Liang, Yuexiang
    Man, Quan
    Li, Haorui
    Guo, Yu
    Zhao, Tiansuo
    CANCER REPORTS, 2023, 6 (12)
  • [23] Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma
    Reni, Michele
    Peretti, Umberto
    Zanon, Silvia
    Macchini, Marina
    Balzano, Gianpaolo
    Mazza, Elena
    Tamburrino, Domenico
    Orsi, Giulia
    Arcidiacono, Paolo Giorgio
    Falconi, Massimo
    Gianni, Luca
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 641 - 650
  • [24] Serum CA19-9 determination in the management of pancreatic cancer
    vandenBosch, RP
    vanEijck, CHJ
    Mulder, PGH
    Jeekel, J
    HEPATO-GASTROENTEROLOGY, 1996, 43 (09) : 710 - 713
  • [25] New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma
    Amburn, Thomas
    Davenport, Daniel
    Patel, Reema
    Moss, Jessica
    Pandalai, Prakash
    Kim, Joseph
    Cavnar, Michael
    AMERICAN SURGEON, 2023, 89 (11) : 4469 - 4478
  • [26] Predictive Value of Preoperative Serum CA19-9 on Margin Status
    Mosquera, Catalina
    Johnson, Helen M.
    Mitsakos, Anastasios T.
    Neill, Nina E.
    Bellamy, Nelly
    Irish, William
    Zervos, Emmanuel E.
    Laks, Shachar
    AMERICAN SURGEON, 2019, 85 (09) : 965 - 972
  • [27] Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma
    Park, Hyung-Doo
    Kang, Eun-Suk
    Kim, Jong-Won
    Lee, Kyu-Taek
    Lee, Kwang Hyuck
    Park, Young Suk
    Park, Joon-Oh
    Lee, Jeeyun
    Heo, Jin Seok
    Choi, Seong Ho
    Choi, Dong Wook
    Kim, Seonwoo
    Lee, Jong Kyun
    Lee, Soo-Youn
    PROTEOMICS, 2012, 12 (23-24) : 3590 - 3597
  • [28] Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
    Lee, Kyong Joo
    Yi, Seung Woo
    Chung, Moon Jae
    Park, Seung Woo
    Song, Si Young
    Chung, Jae Bock
    Park, Jeong Youp
    YONSEI MEDICAL JOURNAL, 2013, 54 (03) : 643 - 649
  • [29] Preoperative CA 19-9 Kinetics as a Prognostic Variable in Radiographically Resectable Pancreatic Adenocarcinoma
    Brown, Erin G.
    Canter, Robert J.
    Bold, Richard J.
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (03) : 293 - 298
  • [30] Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection
    Xu, Junming
    Lyu, Shaocheng
    Zhao, Yang
    Zhang, Xinxue
    Liu, Zhe
    Zhao, Xin
    He, Qiang
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21